Moderna said it manufactured clinical trial material for its COVID-19 vaccine candidate designed specifically to target B.1.351, the coronavirus variant first identified in South Africa, and shipped doses to the National Institutes of Health for a phase 1 study.
Moderna will study three approaches to boosting: a variant-specific booster vaccine candidate, a booster vaccine candidate that combines the drugmaker’s original COVID-19 vaccine with its variant-specific vaccine candidate, and a third dose of the original vaccine.
Pfizer will draw upon its earlier COVID-19 vaccine trial’s participants, who will receive a third shot 6 to 12 months after receiving their initial two doses. The drugmaker also said it is in discussion with the FDA and other regulatory authorities about conducting a clinical trial to evaluate a variant-specific vaccine candidate.
More articles on pharmacy:
CVS expands COVID-19 vaccinations to 17 states
White House again increases weekly vaccine doses sent to states
J&J’s COVID-19 vaccine is safe, effective, FDA review shows
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
